

Docket No.: 27793-00093USPX  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

In re Patent Application of:  
Dorian Bevec

Application No.: 10/517125

Confirmation No.: 5536

Filed: December 1, 2004

Art Unit: N/A

For: USE OF COMPOUNDS HAVING THE  
BIOLOGICAL ACTIVITY OF VASOACTIVE  
INTESTINAL PEPTIDE FOR THE  
TREATMENT OF SARCOIDOSIS

---

Examiner: Not Yet Assigned

**STATEMENT PURSUANT TO 37 CFR §1.821**

MS PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Notification of Missing Requirements, dated August 1, 2005. Applicants are submitting their response herewith within the two-month response period set to expire on October 1, 2005.

Pursuant to Applicants' duty to submit Nucleotide Sequence and/or amino acid sequence information in computer readable form, Applicants' respectfully submit that the content of the SEQUENCE LISTING INFORMATION recorded in computer readable form is identical to the written sequence listing in the above-referenced application.

The U.S. Patent and Trademark Office has taken the position that the previous "Sequence Listing" in computer readable form did not comply with the requirements of Section 1.824 for the stated reason that it contained raw sequence listing errors. Submitted herewith in connection with the above-referenced patent application is a substitute computer readable copy of the Sequence Listing that corrects the defects noted in the raw sequence listing. No new matter has been added to the substitute Sequence Listing.

Applicants respectfully request the above-referenced patent application be placed upon the files for examination.

Dated: August 30, 2005

Respectfully submitted,

By

  
Stanley R. Moore

Registration No.: 26,958

JENKENS & GILCHRIST, A PROFESSIONAL  
CORPORATION

1445 Ross Avenue, Suite 3700

Dallas, Texas 75202

(214) 855-4500

Attorneys For Applicant